Date: 2013-05-29
Type of information: Credit line
Company: Theravectys (France)
Investors: OSEO (France)
Amount: €1.2 million
Funding type: repayable advance
Planned used: These funds will contribute to funding the Phase I/II clinical trials for its anti-HIV therapeutic vaccine based on lentiviral vector technology,currently underway.
Others: * On May 29, 2013, Theravectys, a French biotechnology company developing a new generation of vaccines, has announced it has received funding of €1.2 million from OSEO in the form of a repayable advance as part of the Development of Innovation assistance program (Aide au Développement de l’Innovation) (ADI). This new support from OSEO will contribute to funding the Phase I/II clinical trials for its anti-HIV therapeutic vaccine based on lentiviral vector technology,currently underway. The company expects initial results at the beginning of 2014.
Therapeutic area: Infectious diseases
